Pegaptanib治疗湿性年龄相关性黄斑变性的临床研究

年龄相关性黄斑变性(age-relatedmaculardegeneration,AMD)是发达国家老年人的主要致盲眼病,脉络膜新生血管(choroidalneovascularization,CNV)的形成是湿性AMD患者丧失视力的主要原因。CNV的发生机制尚不清楚,已证实血管内皮生长因子(vascularendothelialgrowthfac-tor,VEGF)是诱发CNV的关键因素之一。Pegaptanib作为眼科领域应用的第一种VEGF抑制剂,通过抑制CNV形成和血管渗漏,对湿性AMD已初步显示出较传统疗法更优越的治疗效果。随着对CNV发生机制的深入研究,针对病因进行治疗,将有可能更加有效的防治湿性AMD等CNV相关疾病。

Clinical researches on Pegaptanib for the treatment of neovascular age-related macular degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness among aged people in developed countries. The formation of choroidal neovascularization (CNV) is responsible for severe central vision loss associated with neovascular AMD. Although little is known on the mechanism of CNV, it is generally believed that vascular endothelial growth factor (VEGF) is implicated as the key factor in the provocation of CNV. Pegaptanib is the first anti-VEGF agent being used in the domain of ophthalmology which is designed to inhibit the formation of CNV and to block the permeability of vessel. It has exhibited a better curative effect than the conventional treatments. As researches on the mechanism of CNV go more deeper, treatments targeting the etiopathogenisis could be possible to help curing AMD and other CNV-related diseases.